O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
middleton MR. et al, (2015), British Journal of Cancer
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
Middleton M., (2015), British Journal of Cancer
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Collins GP. et al, (2015), Br J Haematol, 170, 886 - 890
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.
Stratigos A. et al, (2015), Eur J Cancer, 51, 1989 - 2007
Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE)
Middleton M. et al, (2015), EUROPEAN JOURNAL OF CANCER, 51, S678 - S679
Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
Rasco DW. et al, (2015), EUROPEAN JOURNAL OF CANCER, 51, S53 - S54
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse
Clark L. et al, (2015), EUROPEAN JOURNAL OF CANCER, 51, S686 - S686
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RHI. et al, (2015), J Clin Oncol, 33, 2780 - 2788
Pyrimidine derivatives and guanine derivatives, and their use in treating tumour cells
McMurry TBH. et al, (2015)
A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
Middleton MR. et al, (2015), CANCER RESEARCH, 75
Clinical potential of pacritinib in the treatment of myelofibrosis.
Duenas-Perez AB. and Mead AJ., (2015), Ther Adv Hematol, 6, 186 - 201
Immune checkpoint inhibition in lymphoid disease.
Eyre TA. and Collins GP., (2015), Br J Haematol, 170, 291 - 304
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM. et al, (2015), Lancet Oncol, 16, 928 - 936
The effect of formalizing enhanced recovery after esophagectomy with a protocol.
Findlay JM. et al, (2015), Dis Esophagus, 28, 567 - 573
The effect of formalizing enhanced recovery after esophagectomy with a protocol
Findlay JM. et al, (2015), Diseases of the Esophagus, 28, 567 - 573
Early phase cancer clinical trials: design, ethics and future directions.
Coupe N. et al, (2015), Br J Hosp Med (Lond), 76, 409 - 413
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Mead AJ. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 170, 29 - 39
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ. et al, (2015), Br J Haematol, 170, 29 - 39
Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.
Eyre TA. et al, (2015), Am J Hematol, 90, E103 - E110
Management and controversies of classical Hodgkin lymphoma in pregnancy.
Eyre TA. et al, (2015), Br J Haematol, 169, 613 - 630